Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations

Niu, Mingshan; Shen, Yangling; Qi, Jialei; Liu, Xuejiao; Sang, Wei; Wu, Qingyun; Cao, Jiang; Chen, Wei; Yao, Yao; Xu, Kailin

doi:10.1007/s00277-017-3093-8

Cited by 6 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arsenic is a common, naturally occurring substance that exists in organic and inorganic forms. It has been demonstrated that arsenic can induce cell differentiation and apoptosis (Chen et al, ; Chen, Chen, Shen, Chen, & Wang, ; Niu et al, ; Teng et al, ). Realgar, a mined ore, containing about 90% As 4 S 4, was employed to treat a variety of diseases, including syphilis, malignancy, malaria, and several other parasitic infections with mild toxicity.…”

Section: Discussionmentioning

confidence: 99%

Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells

Zhao

Cai

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease of uncertain etiology that affects multiple tissues and organs. Tetra‐arsenic tetra‐sulfide (As4S4), a traditional Chinese medicine, is effective on acute promyelocytic leukemia with mild side effects. In our previous study, BXSB lupus‐prone mice treated with As4S4 has showed improved monocytosis, decreased serum interleukin (IL)‐6 and suppressed skin, liver and renal lesions with well‐tolerance. In this study, we explored the effect and mechanism of As4S4 on the MRL/lpr mice. MRL/lpr and wild MRL/MpJ mice were divided into control and As4S4 treatment groups and dosed with As4S4 or placebo for 8 weeks. We found that As4S4 prevented the skin, renal and lung lesions of MRL/lpr mice. As4S4 significantly decreased the double negative T (DN T) cells and reduced the serum levels of IL‐17, IL‐10, and antinuclear antibodies titer. Further results revealed that the FasL was decreased, and activated caspases elevated in DN T cells in As4S4 treated MRL/lpr mice. Taken together, As4S4 could selectively suppresses DN T cells by inducing apoptosis. It also reduced inflammatory cytokines IL‐17, which may be produced by DN T cells. As4S4 may represent a new therapy for SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells

Zhao

Cai

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The diagnostic and prognostic importance of cytogenetic and molecular abnormalities in AML is well accepted (Dohner et al, ; Niu et al, ). For instance, NPM1 and biallelic CEBPA mutations are associated with favorable outcomes in patients with cytogenetically normal AML (Heath et al, ; Taskesen et al, ).…”

Section: Introductionmentioning

confidence: 99%

High expression of miR‐338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy

Gao

et al. 2019

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous disease with unfavorable outcomes. MicroRNAs (miRNAs) are important regulators and prognostic factors involved in AML. To determine the clinical role of miR-338 in AML, a total of 164 adults with de novo AML were collected. These patients were classified into a chemotherapy group and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) group according to the clinical treatment, and then each group was divided into two subgroups based on the median miR-338 expression values. We found that upregulated miR-338 positively correlates with higher frequencies of complex karyotype, RUNX1 mutation, and poor risk status. In the chemotherapy group, high expression of miR-338 was independently associated with shorter EFS and OS.However, no significant differences were observed between the two subgroups within the allo-HSCT group. We also divided all patients into two groups according to the median miR-338 expression values of the whole cohort. In the miR-338 high expression group, patients receiving allo-HSCT had longer OS and EFS than those receiving chemotherapy only. In contrast, patients receiving different therapies had similar OS and EFS in the miR-338 low expression group. Our study suggests that high expression of miR-338 is an adverse prognostic biomarker in patients with AML undergoing chemotherapy and may guide treatment decisions for AML. Furthermore, allo-HSCT could significantly overcome the negative effect of high miR-338 expression, but it seemed to be unbeneficial and unnecessary for low miR-338 expressions.

show abstract

“…The clinical prognosis of patients with AML is various. The differences in outcomes among AML patients depend on multiple intrinsic factors [2, 3]. With the development of methodologies of massive sequencing, it has been demonstrated that somatic mutations in NPM1, FLT3, CEBPA, IDH1 and IDH2 are connected to prognosis in AML [4].…”

Section: Introductionmentioning

confidence: 99%

High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) pertains to a hematologic malignancy with heterogeneous therapeutic responses. Improvements in risk stratification in AML patients are warranted. MicroRNAs have been associated with the pathogenesis of AML. Methods To examine the prognostic value of miR-25, 162 cases with de novo AML were classified into two groups according to different treatment regimens. Results In the chemotherapy group, cases with upregulated miR-25 expression showed relatively longer overall survival (OS; P = 0.0086) and event-free survival (EFS; P = 0.019). Multivariable analyses revealed that miR-25 upregulation is an independent predictor for extended OS (HR = 0.556, P = 0.015) and EFS (HR = 0.598, P = 0.03). In addition, allogeneic hematopoietic stem cell transplantation (allo-HSCT) circumvented the poor prognosis that was related to miR-25 downregulation with chemotherapy. The expression level pattern of miR-25 coincided with AML differentiation and proliferation, which included HOXA and HOXB cluster members, as well as the HOX cofactor MEIS1. The MYH9 gene was identified as a direct target of miR-25. Conclusions The miR-25 levels are correlated with prognosis in AML independently of other powerful molecular markers. The expression of miR-25 may contribute to the selection of the optimal treatment regimen between chemotherapy and allo-HCST for AML patients.

show abstract

Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations

Cited by 6 publications

References 10 publications

Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells

Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells

High expression of miR‐338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy

High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia

Contact Info

Product

Resources

About